|
1
|
Vansteenkiste JF, Cho BC, Vanakesa T, De
Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J,
Nakayama H, et al: Efficacy of the MAGE-A3 cancer immunotherapeutic
as adjuvant therapy in patients with resected MAGE-A3-positive
non-small-cell lung cancer (MAGRIT): A randomised, double-blind,
placebo-controlled, phase 3 trial. Lancet Oncol. 17:822–835.
2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Xiang B, Snook AE, Magee MS and Waldman
SA: Colorectal cancer immunotherapy. Discov Med. 15:301–308.
2013.PubMed/NCBI
|
|
3
|
Mittendorf EA, Lu B, Melisko M, Price
Hiller J, Bondarenko I, Brunt AM, Sergii G, Petrakova K and Peoples
GE: Efficacy and safety analysis of Nelipepimut-S vaccine to
prevent breast cancer recurrence: A randomized, multicenter, phase
III clinical trial. Clin Cancer Res. 25:4248–4254. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Clifton GT, Hale D, Vreeland TJ, Hickerson
AT, Litton JK, Alatrash G, Murthy RK, Qiao N, Philips AV, Lukas JJ,
et al: Results of a randomized phase IIb trial of Nelipepimut-S +
Trastuzumab versus Trastuzumab to prevent recurrences in patients
with high-risk HER2 low-expressing breast cancer. Clin Cancer Res.
26:2515–2523. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Harper DM, Franco EL, Wheeler CM, Moscicki
AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa
Clemens SA and Dubin G: HPV Vaccine Study group. Sustained efficacy
up to 4.5 years of a bivalent L1 virus-like particle vaccine
against human papillomavirus types 16 and 18: Follow-up from a
randomised control trial. Lancet. 367:1247–1255. 2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Rosenbaum P, Artaud C, Bay S, Ganneau C,
Campone M, Delaloge S, Gourmelon C, Loirat D, Medioni J, Pein F, et
al: The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine
induces tumor-specific cytotoxic antibodies in breast cancer
patients. Cancer Immunol Immunother. 69:703–716. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gupta S, McDonald JD, Ayabe RI, Khan TM,
Gamble LA, Sinha S, Hannah C, Blakely AM, Davis JL and Hernandez
JM: Targeting CA 19-9 with a humanized monoclonal antibody at the
time of surgery may decrease recurrence rates for patients
undergoing resections for pancreatic cancer, cholangiocarcinoma and
metastatic colorectal cancer. J Gastrointest Oncol. 11:231–235.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
van der Meijden PM, van Klingeren B,
Steerenberg PA, de Boer LC, de Jong WH and Debruyne FM: The
possible influence of antibiotics on results of bacillus
Calmette-Guérin intravesical therapy for superficial bladder
cancer. J Urol. 146:444–446. 1991.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Schwartzentruber DJ, Lawson DH, Richards
JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K,
Pockaj B, et al: gp100 peptide vaccine and interleukin-2 in
patients with advanced melanoma. N Engl J Med. 364:2119–2127.
2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bezu L, Kepp O, Cerrato G, Pol J, Fucikova
J, Spisek R, Zitvogel L, Kroemer G and Galluzzi L: Trial watch:
Peptide-based vaccines in anticancer therapy. Oncoimmunology.
7(e1511506)2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sasada T, Yamada A, Noguchi M and Itoh K:
Personalized peptide vaccine for treatment of advanced cancer. Curr
Med Chem. 21:2332–2345. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Noguchi M, Sasada T and Itoh K:
Personalized peptide vaccination: A new approach for advanced
cancer as therapeutic cancer vaccine. Cancer Immunol Immunother.
62:919–929. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Narita Y, Arakawa Y, Yamasaki F, Nishikawa
R, Aoki T, Kanamori M, Nagane M, Kumabe T, Hirose Y, Ichikawa T, et
al: A randomized, double-blind, phase III trial of personalized
peptide vaccination for recurrent glioblastoma. Neuro Oncol.
21:348–359. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Noguchi M, Fujimoto K, Arai G, Uemura H,
Hashine K, Matsumoto H, Fukasawa S, Kohjimoto Y, Nakatsu H,
Takenaka A, et al: A randomized phase III trial of personalized
peptide vaccination for castration-resistant prostate cancer
progressing after docetaxel. Oncol Rep. 45:159–168. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Suekane S, Yutani S, Yamada A, Sasada T,
Matsueda S, Takamori S, Toh U, Kawano K, Yoshiyama K, Sakamoto S,
et al: Identification of biomarkers for personalized peptide
vaccination in 2,588 cancer patients. Int J Oncol. 56:1479–1489.
2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Matsueda S, Itoh K and Shichijo S:
Antitumor activity of antibody against cytotoxic T lymphocyte
epitope peptide of lymphocyte-specific protein tyrosine kinase.
Cancer Sci. 109:611–617. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Noguchi M, Koga N, Moriya F, Suekane S,
Yutani S, Yamada A, Shichijo S, Kakuma T and Itoh K: Survival
analysis of multiple peptide vaccination for the selection of
correlated peptides in urological cancers. Cancer Sci.
109:2660–2669. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Taskén K: Waking up regulatory T cells.
Blood. 114:1136–1137. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Bardhan K, Patsoukis N, Weaver J, Freeman
G, Li L and Boussiotis VA: PD-1 inhibits the TCR signaling cascade
by sequestering SHP-2 phosphatase, preventing its translocation to
lipid rafts and facilitating Csk-mediated inhibitory
phosphorylation of Lck. J Immunol 196 (Suppl 1). 128(15)2016.
|
|
22
|
Dunn GP, Old LJ and Schreiber RD: The
three Es of cancer immunoediting. Annu Rev Immunol. 22:329–360.
2004.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Thomas R, Al-Khadairi G, Roelands J,
Hendrickx W, Dermime S, Bedognetti D and Decock J: NY-ESO-1 based
immunotherapy of cancer: Current perspectives. Front Immunol.
9(947)2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zitvogel L, Ayyoub M, Routy B and Kroemer
G: Microbiome and anticancer immunosurveillance. Cell. 165:276–287.
2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sivan A, Corrales L, Hubert N, Williams
JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B,
Alegre ML, et al: Commensal Bifidobacterium promotes antitumor
immunity and facilitates anti-PD-L1 efficacy. Science.
350:1084–1089. 2015.PubMed/NCBI View Article : Google Scholar
|
